Gabapentin
Product Images NDC 17856-0698

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 17856-0698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 0698 01 Label)

Drug Facts and product information panel for Gabapentin oral solution 250 mg per 5 mL. It includes dosage per cup, storage instructions to refrigerate at 2-8°C, manufacturer and distributor details, and a barcode with NDC 17856-0698-01. The label notes this is a prescription product and advises keeping it out of children's reach.*

FDA Label Image

Image Description (17856 0698 02 Label)

Drug Facts panel for Gabapentin oral solution 300 mg per 6 mL. Includes dosage per cup, storage instructions to refrigerate at 2-8°C, manufacturer Anneal Pharmaceuticals LLC, repackager Unit Dose Solutions, Inc., and distributor Atlantic Biologicals Corp. Also provides a contact phone number for questions, lot numbers, expiration date placeholders, and a barcode.*

FDA Label Image

Image Description (Gabapentin Oral Solution 1)

A chemical structure diagram showing a formula for creatinine clearance (CLCr) calculation. It includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. This formula estimates kidney function.*

FDA Label Image

Image Description (Gabapentin Oral Solution 2)

Chemical structure diagram of Gabapentin showing its cyclohexane ring attached to amino (CH2NH2) and carboxyl (CH2CO2H) groups.*

FDA Label Image

1 (Gabapentin Oral Solution 3)

A line graph showing the mean pain score over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain score, with Gabapentin showing a decreasing trend compared to the relatively stable placebo line.*

FDA Label Image

2 (Gabapentin Oral Solution 4)

A line graph illustrating mean pain scores over a 7-week period comparing three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph shows a 3-week dose titration period followed by a 4-week fixed dose period, with mean pain scores decreasing more for the Gabapentin groups than placebo.*

FDA Label Image

1 (Gabapentin Oral Solution 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies'. It displays data from two studies comparing placebo (PBO) and different doses of Gabapentin (GBP 3600 for Study 1; GBP 1800 and GBP 2400 for Study 2). The chart shows higher responder proportions in Gabapentin groups versus placebo, with significance levels indicated as ** (p < 0.01) and *** (p < 0.001).*

FDA Label Image

1 (Gabapentin Oral Solution 6)

A scatter plot chart comparing the percentage difference versus daily dose (mg) for Gabapentin across three studies labeled as Study a, Study b, and Study c. The x-axis represents increasing daily doses from 600 to 1800 mg, while the y-axis shows the difference percentage from 2% to 22%. Each study uses distinct markers and the plots illustrate dose-related differences for Gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.